Biotech firm Imunon's Q3 net loss widens
IMNN•Imunon's Q3 net loss to common shareholders was $3.81 million, with operating expenses of $3.45 million. The company reduced outstanding debt by 43% through a debt-for-equity exchange and agreed to sell ThermoDox rights for potential milestone payments and royalties.
1. Quarterly results
Imunon reported a Q3 net loss to common shareholders of $3.81 million and a loss per share of $0.64. Operating expenses were $3.45 million, with research and clinical costs for its OVATION studies among the primary expense drivers.
2. Debt and development
The company reduced outstanding debt by 43% through a debt-for-equity exchange in Q3 and agreed to sell ThermoDox rights for potential milestone payments and royalties. Imunon expects to complete enrollment in its Phase 3 OVATION 3 study by Q1 2029 and plans to advance IMNN-001 clinical development with support from the National Cancer Institute.
